CPIX CUMBERLAND PHARMACEUTICALS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.8

Period return

+3.63 (+167.28%)

Volume

62.2K

2026-06-05O $5.79 H $5.88 L $5.56 C $5.8MA5 $5.74MA20 $5.45MA60 $4.09MA120 $4.07

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2019. 12. 03.LowBUY7 years ago
B. Riley Securities: Buy
US analyst rating / recommendation change.
2019. 11. 19.LowBUY7 years ago
B. Riley Securities: Buy
US analyst rating / recommendation change.
2018. 08. 17.LowBUY8 years ago
B. Riley Securities: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Sector

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 04.	After market close (AMC)	—	—	—	—	—	Scheduled
FY2025 Q1	2025. 03. 31.	Time TBD	—	$0.08	—	—	$11.71M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.32	—	—	$27.43M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.21	—	—	$18.35M	Reported

Date	Firm	Analyst	Action	Rating change	Price target	Report
2019. 12. 03.	B. Riley Securities	—	Maintain	— → Buy	—	B. Riley Securities: Buy
2019. 11. 19.	B. Riley Securities	—	Maintain	— → Buy	—	B. Riley Securities: Buy
2018. 08. 17.	B. Riley Securities	—	Maintain	Buy → Buy	—	B. Riley Securities: Buy
2018. 04. 17.	B. Riley Securities	—	Initiate coverage	— → Buy	—	B. Riley Securities: Buy
2013. 04. 10.	UBS	—	Maintain	— → Neutral	—	UBS: Neutral
2012. 11. 13.	UBS	—	Maintain	— → Neutral	—	UBS: Neutral

CUMBERLAND PHARMACEUTICALS INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats